Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:51:17.310Z.
Calculation as of: 2026-10-06T18:51:17.310Z.
Quote observation: 2026-10-06T18:50:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d443e069440aa0ac5a32f25afa0d38c48efe58a411ec60778b8439bb1c5cf92a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$192.84M
PS Ratio
N/A
TTM Avg
4.26
3Y Avg
5.68
5Y Avg
5.68
Market Cap
$183.55M
PS Ratio
122.71
TTM Avg
325.04
3Y Avg
325.04
5Y Avg
325.04
Market Cap
$182.79M
PS Ratio
N/A
TTM Avg
344.10
3Y Avg
344.10
5Y Avg
344.10
Market Cap
$180.89M
PS Ratio
N/A
TTM Avg
59.22
3Y Avg
66.85
5Y Avg
93.69
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | $189.50M | N/A | N/A | N/A | N/A |
| RxSight, Inc. (RXST)vs › | $191.67M | 1.50 | 2.25 | 8.69 | 10.18 |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $192.84M | N/A | 4.26 | 5.68 | 5.68 |
| AN2 Therapeutics, Inc. (ANTX)vs › | $184.40M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.55M | 122.71 | 325.04 | 325.04 | 325.04 |
| Compass Therapeutics, Inc. (CMPX)vs › | $182.79M | N/A | 344.10 | 344.10 | 344.10 |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $180.89M | N/A | 59.22 | 66.85 | 93.69 |
| Surrozen, Inc. (SRZN)vs › | $199.57M | 17.34 | 45.56 | 20.70 | 17.35 |
| Yarrow Bioscience Inc (YARW)vs › | $178.83M | 371.02 | 47.26 | 105.68 | 69.39 |
| Alector, Inc. (ALEC)vs › | $201.06M | 14.50 | 8.68 | 5.87 | 7.02 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-19 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
